Dipan Mehta of Elixir Equities prefers pharma and specialty chemicals for medium-term investments, remains cautious on IT amid AI uncertainty, and suggests exiting Info Edge stock.
Dipan Mehta of Elixir Equities prefers pharma and specialty chemicals for medium-term investments, remains cautious on IT amid AI uncertainty, and suggests exiting Info Edge stock.